N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.
复制标题
DOI：
10.1182/blood.v76.4.801.bloodjournal764801
复制
发表时间：
1990-08
期刊：
影响因子：
20.3
通讯作者：
J. Radich;K. Kopecky;C. Willman;James K. Weick;David R. Head;Frederick R. Appelbaum;Steven J. Collins
中科院分区：
文献类型：
--
作者：
J. Radich;K. Kopecky;C. Willman;James K. Weick;David R. Head;Frederick R. Appelbaum;Steven J. Collins
N-ras原癌基因的点突变先前已在20%至60%的急性髓细胞性白血病（AML）样本中检测到，但这些突变的临床意义目前尚不清楚。我们直接测序聚合酶链反应（PCR）扩增的N-ras片段，以确定55例成人初发AML患者的N-ras点突变频率。55例患者中有8例（15%）存在突变。这些突变通常发生在密码子12、13或61，但1例患者同时发生在密码子13和61，另1例患者在N-ras密码子60发生了不寻常的点突变。比较有N-ras突变和无N-ras突变的患者，除N-ras突变患者FAB M4亚型的百分比可能较高外，在治疗前临床变量、诱导治疗应答或生存率方面无统计学显著差异。这些数据与以前的报告一起表明，N-ras点突变的存在并不能清楚地定义AML患者的独特临床或生物学亚群。
Point mutations of the N-ras proto-oncogenes have been previously detected in 20% to 60% of samples of acute myelogenous leukemia (AML), but the clinical significance of these mutations is presently unclear. We directly sequenced polymerase chain reaction (PCR) amplified N-ras fragments to determine the frequency of N-ras point mutations in 55 adult patients with de novo AML. Mutations were present in 8 of 55 (15%) patients. These mutations were usually in codon 12, 13, or 61, but one patient had mutations in both codons 13 and 61, and another had an unusual point mutation in N-ras codon 60. A comparison of patients with and without N-ras mutations showed no statistically significant differences in pretreatment clinical variables, response to induction therapy, or survival, except for a possibly higher percentage of FAB M4 subtypes in patients with the N-ras mutation. These data together with previous reports suggest that the presence of N-ras point mutations do not clearly define a unique clinical or biologic subset of AML patients.